Rallybio Corporation
NASDAQ Capital MarketTotal Valuation
Rallybio Corporation carries a market capitalization of 85.14M, placing it among publicly traded companies globally. Its enterprise value stands at 3.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 85.14M |
| Enterprise Value | 3.97M |
Share Statistics
Rallybio Corporation currently has 5.29M shares outstanding.
| Shares Outstanding | 5.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 58.98, and the price-to-book ratio stands at -0.16.
| PE Ratio | N/A |
| PS Ratio | 58.98 |
| PB Ratio | -0.16 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | -1.83 |
| P/OCF Ratio | -1.83 |
Enterprise Valuation
| EV / Sales | 4.62 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Rallybio Corporation maintains a current ratio of 12.92, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.92 |
| Quick Ratio | 11.30 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -13.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 4.91 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Rallybio Corporation's stock has gained approximately 433.88704% over the past 52 weeks. The 50-day moving average sits at 11.10, while the 200-day moving average is 6.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | 433.88704% |
| 50-Day Moving Average | 11.10 |
| 200-Day Moving Average | 6.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Rallybio Corporation generated 858,000.00 in revenue and converted that into -7.82M in net income, yielding earnings per share of -1.39. EBITDA reached -32.06M, while operating income came in at -32.13M.
| Revenue | 858,000.00 |
| Gross Profit | N/A |
| Operating Income | -32.13M |
| Pretax Income | -7.53M |
| Net Income | -7.82M |
| EBITDA | -32.06M |
| EBIT | -32.13M |
| Earnings Per Share (EPS) | -1.39 |
Balance Sheet
Rallybio Corporation holds 46.80M in cash and equivalents against 154,000.00 in total debt, resulting in a net debt position of -41.30M. Total book value stands at -310.27M, with working capital of 49.35M providing operational flexibility.
| Cash & Cash Equivalents | 46.80M |
| Total Debt | 154,000.00 |
| Net Debt | -41.30M |
| Equity (Book Value) | -310.27M |
| Book Value Per Share | -54.99 |
| Working Capital | 49.35M |
Cash Flow
Rallybio Corporation produced -27.59M in operating cash flow over the past twelve months.
| Operating Cash Flow | -27.59M |
| Capital Expenditures | N/A |
| Free Cash Flow | -27.59M |
| FCF Per Share | -4.89 |
Margins
Rallybio Corporation operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,744.41 and net profit margin of -911.07 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3,744.41 |
| Pretax Margin | -877.62 |
| Profit Margin | -911.07 |
| EBITDA Margin | -3,736.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.04 |
| FCF Yield | -54.51 |
Stock Splits
Rallybio Corporation's most recent stock split took place on February 6, 2026 with a 8:1 split ratio.
| Last Split Date | 2/6/2026 |
| Split Ratio | 8:1 |
Scores
Rallybio Corporation posts an Altman Z-Score of -1.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.58 |